To improve the efficacy of the dendritic cell vaccine Alv B DC from Alv B, the PD-L1 expression in cancer cells was attempted to be reduced through a transfection with a custom designed siRNA. Before transfecting the dendritic cells, the siRNA functionality had to be tested through flow cytometry, that resulted in negative results and therefore led to a RT-qPCR protocol that indicated that the siRNA was functional. Protocols for the two methods were developed and a cell line expressing PD-L1 was set up as a tool for testing. The final goal of testing the effects in Alv B DC was never performed due compromising time but the positive result from the PCR provides a promising start to further testing.
| Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:kau-95172 |
| Date | January 2023 |
| Creators | Berglund, Felicia |
| Publisher | Karlstads universitet |
| Source Sets | DiVA Archive at Upsalla University |
| Language | English |
| Detected Language | English |
| Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
| Format | application/pdf |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0014 seconds